GIRGENTI STEVEN

SEC source: 0001493152-22-030872 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 7,657

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F3 · shares: In connection with the IPO Closing on September 6, 2022, the $32,161.64 of outstanding principal and accrued but unpaid interest of this secured convertible promissory note (a "Note"), dated February 7, 2019, automatically converted into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

F3 · price: In connection with the IPO Closing on September 6, 2022, the $32,161.64 of outstanding principal and accrued but unpaid interest of this secured convertible promissory note (a "Note"), dated February 7, 2019, automatically converted into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis).

F2 · ownership.nature: These securities are owned directly by the Cranye Girgenti Testamentary Trust (the "Trust"), and indirectly by Mr. Girgenti as co-trustee of the Trust. Mr. Girgenti disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001493152-22-030872 · ownership.xml · derivative · entry 33

GIRGENTI STEVEN · CIK 0001055530 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,916

Underlying: Common Stock · 40,916 shares

Expires 2027-08-31

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F18 · derivative.exercise_price: The reported securities are included within 40,916 Units purchased by Mr. Girgenti for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.

F18 · price: The reported securities are included within 40,916 Units purchased by Mr. Girgenti for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.

SEC source: 0001493152-22-030872 · ownership.xml · derivative · entry 32

GIRGENTI STEVEN · CIK 0001055530 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,916

Underlying: Common Stock · 40,916 shares

Expires 2027-08-31

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F18 · derivative.exercise_price: The reported securities are included within 40,916 Units purchased by Mr. Girgenti for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.

F18 · price: The reported securities are included within 40,916 Units purchased by Mr. Girgenti for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.

SEC source: 0001493152-22-030872 · ownership.xml · nonDerivative · entry 16

GIRGENTI STEVEN · CIK 0001055530 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 861,099

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F18 · price: The reported securities are included within 40,916 Units purchased by Mr. Girgenti for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share.

SEC source: 0001493152-22-030872 · ownership.xml · derivative · entry 39

GIRGENTI STEVEN · CIK 0001055530 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 2,380

Underlying: Common Stock · 2,380 shares

Expires 2027-07-20

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F24 · price: Represents a right to purchase 2,380 shares of Common Stock underlying a warrant at an exercise price of $5.25 per share. The warrant was issued to the Trust on July 20, 2022 as consideration for the Trust's agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Note issued to the Trust under the Note Purchase Agreement from August 31, 2022 to October 31, 2022..

F2 · ownership.nature: These securities are owned directly by the Cranye Girgenti Testamentary Trust (the "Trust"), and indirectly by Mr. Girgenti as co-trustee of the Trust. Mr. Girgenti disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001493152-22-030872 · ownership.xml · derivative · entry 38

GIRGENTI STEVEN · CIK 0001055530 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,811

Underlying: Common Stock · 123,811 shares

Expires 2027-07-20

F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").

F23 · shares: Represents a right to purchase 123,811 shares of Common Stock underlying 10 warrants at an exercise price of $5.25 per share. The warrants were issued to Mr. Girgenti on July 20, 2022 as consideration for his agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Notes issued to him under the Note Purchase Agreement from August 31, 2022 to October 31, 2022.

F23 · price: Represents a right to purchase 123,811 shares of Common Stock underlying 10 warrants at an exercise price of $5.25 per share. The warrants were issued to Mr. Girgenti on July 20, 2022 as consideration for his agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Notes issued to him under the Note Purchase Agreement from August 31, 2022 to October 31, 2022.

SEC source: 0001493152-21-008263 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 625,449

SEC source: 0001493152-21-000737 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 592,116

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-20-019046 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 558,783

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-20-012775 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 525,450

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-20-005944 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 492,117

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-20-000287 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 458,784

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-19-015294 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 425,451

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-19-010161 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 392,118

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-19-004810 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358,785

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-19-000307 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,452

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-18-014775 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 292,119

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-18-009840 · ownership.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 267,981

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-18-004740 · form4.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 246,769

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-18-000081 · form4.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,186

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-17-011379 · form4.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,267

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-17-008079 · form4.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,267

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

F2 · balance_after: Includes an adjustment of 7,387 shares based upon a calculation error in the reporting person's report as of October 31, 2016.

SEC source: 0001493152-17-003586 · form4.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,547

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001493152-17-000450 · form4.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,214

F1 · shares: Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director.

SEC source: 0001354488-16-008370 · issuerdirect_section16.xml · nonDerivative · entry 1

GIRGENTI STEVEN · CIK 0001055530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,002